SHANGHAI/LONDON: GlaxoSmithKline said on Monday it was investigating new allegations that its staff had used improper tactics to market Botox in China, but had so far found no evidence of bribery or corruption.
The move follows a claim that GSK staff allegedly handed doctors cash and other rewards for prescribing Botox treatment, which the British group sells in China under an agreement with patent-holder Allergan.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!